A new iData Research report examines leading trends in the orthopedic biomaterials market.
Here are six things to know about the market:
1. The United States orthopedic biomaterials market is expected to reach nearly $3.88 billion by 2021.
2. The market for hyaluronic acid viscosupplementation used for osteoarthritis patients to delay total knee replacement is expected to reach around $1 billion by 2017.
3. The market for hyaluronic acid products is shifting from five injections to three injections, and even further to one injection despite the slightly higher selling price for one injection.
4. Despite the shift toward single injection treatments, the multi-injection products will remain a leader in the market place overall for the next few years.
5. Medtronic has more than 20 percent of the orthopedic biomaterials market share, including their line of growth factor bone graft products.
6. Genzyme is Medtronic's market competitor, holding around 10 percent of the orthopedic biomaterials market with a majority market share in the hyaluronic acid viscosupplementation segment.